Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Steps For NEST: Planning Board Lays Out Launch Strategy For Evaluation System

Executive Summary

A public-private National Evaluation System for health Technology (NEST) is gathering momentum following a recent funding agreement in the draft Medical Device User Fee Act IV deal. A planning board tasked with developing a NEST coordinating center has outlined projects to get the system off the ground. Also: Listen to our podcast interview with Mark McClellan about the project.

You may also be interested in...



FDA Turns Adverse-Event Reporting Scrutiny On Hospitals

The US agency detailed potential adverse-event reporting violations at 15 hospitals in FDA-483 forms that were posted online by FDA to highlight the need to shift to an active, electronic based device surveillance system.

Podcast: Mark McClellan Explains New NEST Recommendations

In this interview, Mark McClellan, the Duke-Margolis Center director and health-policy expert, discusses new planning-board proposals for the National Evaluation System for health Technology, which US FDA envisions as a paradigm shift for device data collection.

MDIC Snags $3m For FDA Real-World Evidence Coordinating Center

FDA has awarded the Medical Device Innovation Consortium $3 million to create a "coordinating center" to develop an envisioned National Evaluation System for health Technology, which will leverage real-world evidence to support device approvals and safety and performance tracking.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel